Early ICU Admission Of Newly Diagnosed Acute Myeloid Leukemia With No Organ Failure

Author:

Elkaim Elodie1,Mokart Djamel2,Vey Norbert1,Charbonnier Aude1,D’Incan Evelyne1,Rey Jerome1,Prebet Thomas1,Brun Jean-Paul2,Sannini Antoine2,Picard Muriel3,Recher Christian3,Etienne Anne1

Affiliation:

1. Hematology Department, Institut Paoli Calmettes, Marseille, France,

2. Intensive Care Unit, Institut Paoli Calmettes, Marseille, France,

3. Hematology Department, Hopital Purpan, Toulouse, France

Abstract

Abstract Background and Aim Acute myeloid leukemia (AML) at diagnosis can be an emergency. Induction mortality reaches 5 to 15% for patients under 60 years of age, and 15 to 30% for subjects over 60. 10 to 34% of patients will require a shift to intensive care unit (ICU) during induction and most of organ failures occur in the first few days. To optimize and improve the initial management of AML, we selected patients with high risk of induction mortality based on white blood cell count (WBC) ≥ 50 G/l and thrombocytopenia ≤ 50G/l at diagnosis. These patients were systematically admitted into ICU even without organ failure. Patients and Methods Our study was conducted in two hospitals, between 1st January 2000 and 31thDecember 2010. We included patients with newly diagnosed AML, aged 18 to 75 years, with both WBC ≥ 50G/l and platelets ≤ 50G/l, and no organ failure (group 1). 41 patients transferred to ICU based on conventional criteria (organ failure) during this period were not included in the study. Patients were directly admitted in ICU for diagnosis and treatment of AML(induction chemotherapy), and were jointly managed by both the intensivist and the hematologist. Patients were discharged from ICU without any non-hematological organ failure. Results were compared to a control group of similar patients admitted in another university hospital were high-risk patients are managed conventionnaly (ie no systematic ICU transfer in the absence of organ failure) (group 2). We defined organ failure by the requirement of mechanical ventilation for respiratory deficiency, renal remplacement therapy for renal failure, vaso-active drugs for hemodynamic and heart failure and when glasgow score was<7 for neurological failure. Results 130 patients were included, 50 patients in group 1 and 79 patients in group 2. Neither age at diagnosis and AML characteristics differed significantly between the two groups, nor complete remission rate(80% versus 70,5%) and relapse rate(55% versus 49%). 18 patients (36%) presented organ failure in group 1, 9 (11%) in group 2. The median time between induction and organ failure was 1 day(1-6) in group 1 and 3 days (1-24) in group 2. The main organ failure was acute respiratory failure, with 10 patients (56%) who needed invasive mechanical ventilation in group 1 and 8 (89%) in group 2. In group 1, renal replacement therapy and vaso-active drugs was used in 4 (22%) and 6 (33%) patients, respectively, versus 3 (33%) and 7 patients (78%), respectively, in group 2. The median length of stay in ICU was 5 days in patients without organ failure in group 1 (2-18), 11,5 days in patients with organ failure in group 1 (4-45), and 6 days in group 2 (1-37). Overall survival was not significantly different between the two groups (p 0.28). Six patients (12%) died in the group 1 at day 30 of induction chemotherapy, 14 patients (18%) in the group 2. Concerning patients who developed organ failure, the 30 days survival was significantly better in patients already monitored in ICU (group 1), 67 %, versus 22% in group 2 (p=0.02). The overall survival of patients of group 1 who had presented organ failure but alive after their ICU stay, was not statistically different compared to patients of group 1 without organ failure during induction (median 8 months versus 16 months, p 0,09). Conclusion There were more critical patients in the study group, but their 30 days survival was significantly better than in patients with organ failure in the control group. However, overall survival of the two groups was comparable. This study highlights a new strategy to improve initial management of AML. The rapid onset of complications (<3 days in more than 90%) allows considering short stays in ICU for patients who will not presented organ failure in the first 3 days of induction. The main limiting factor for this management is its applicability. These results have to be confirmed by a multicentric comparative study. Disclosures: No relevant conflicts of interest to declare.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3